Profile data is unavailable for this security.
About the company
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
- Revenue in USD (TTM)37.89m
- Net income in USD-12.13m
- Incorporated2017
- Employees44.00
- LocationEquillium Inc2223 Avenida de La Playa Ste 105LA JOLLA 92037-3217United StatesUSA
- Phone+1 (858) 412-5302
- Fax+1 (302) 636-5454
- Websitehttps://www.equilliumbio.com/home/default.aspx
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Modular Medical Inc | 0.00 | -16.76m | 50.51m | 37.00 | -- | 9.03 | -- | -- | -0.9653 | -0.9653 | 0.00 | 0.1805 | 0.00 | -- | -- | 0.00 | -224.40 | -168.16 | -262.22 | -209.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.51 | -- | 154.53 | -- |
Kezar Life Sciences Inc | 7.00m | -101.87m | 50.52m | 58.00 | -- | 0.2693 | -- | 7.22 | -1.40 | -1.40 | 0.0965 | 2.58 | 0.0269 | -- | -- | 120,689.70 | -39.12 | -32.54 | -41.41 | -34.09 | -- | -- | -1,455.29 | -4,308.11 | -- | -- | 0.051 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
Ocean Biomedical Holdings Inc | 0.00 | -45.58m | 50.93m | 9.00 | -- | -- | -- | -- | -1.40 | -1.40 | 0.00 | -0.0642 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -612.50 | -- | -- | -- |
CASI Pharmaceuticals Inc | 28.94m | -30.48m | 51.78m | 176.00 | -- | 3.35 | -- | 1.79 | -2.28 | -2.28 | 2.16 | 1.15 | 0.3954 | 1.00 | 3.41 | 164,437.50 | -40.88 | -34.75 | -59.15 | -46.91 | 58.36 | 55.98 | -103.40 | -153.72 | 3.25 | -76.70 | 0.5458 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
Carmell Corp | 0.00 | -18.29m | 51.80m | 9.00 | -- | -- | -- | -- | -1.58 | -1.49 | 0.00 | -0.0719 | 0.00 | -- | -- | 0.00 | -428.46 | -- | -- | -- | 58.60 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -75.70 | -- | -- | -- |
Bright Green Corp | 0.00 | -11.46m | 52.24m | 5.00 | -- | 4.70 | -- | -- | -0.0631 | -0.0631 | 0.00 | 0.0584 | 0.00 | -- | -- | 0.00 | -56.05 | -- | -84.87 | -- | -- | -- | -- | -- | -- | -18,125.84 | 0.0289 | -- | -- | -- | 52.54 | -- | -- | -- |
IN8BIO, Inc. | 0.00 | -31.04m | 52.51m | 31.00 | -- | 2.94 | -- | -- | -0.9154 | -0.9154 | 0.00 | 0.4049 | 0.00 | -- | -- | 0.00 | -123.61 | -74.18 | -145.63 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0556 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
Equillium Inc | 37.89m | -12.13m | 52.88m | 44.00 | -- | 2.51 | -- | 1.40 | -0.3476 | -0.3476 | 1.08 | 0.5983 | 0.6568 | -- | 8.95 | 861,227.30 | -21.02 | -46.81 | -39.66 | -57.36 | -- | -- | -32.01 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
DURECT Corp | 8.32m | -23.28m | 53.08m | 48.00 | -- | 6.39 | -- | 6.38 | -0.8653 | -0.8653 | 0.2976 | 0.2674 | 0.176 | 0.7021 | 6.87 | 143,465.50 | -49.23 | -37.34 | -167.81 | -53.44 | 80.56 | 91.83 | -279.77 | -139.11 | 0.9575 | -47.70 | 0.6377 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
Anebulo Pharmaceuticals Inc | 0.00 | -9.35m | 53.16m | 2.00 | -- | 10.66 | -- | -- | -0.3633 | -0.3633 | 0.00 | 0.1922 | 0.00 | -- | -- | 0.00 | -91.51 | -- | -104.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
Rockwell Medical Inc | 86.62m | -8.42m | 53.20m | 237.00 | -- | 2.51 | -- | 0.6142 | -0.3584 | -0.3584 | 3.33 | 0.6984 | 1.90 | 13.28 | 10.12 | 365,485.20 | -18.47 | -46.29 | -27.53 | -65.38 | 10.59 | 4.66 | -9.72 | -36.51 | 1.38 | -3.54 | 0.331 | -- | 14.84 | 5.69 | 54.82 | -- | 76.21 | -- |
Arca Biopharma Inc | 0.00 | -6.00m | 53.68m | 4.00 | -- | 1.53 | -- | -- | -0.4155 | -0.4155 | 0.00 | 2.42 | 0.00 | -- | -- | 0.00 | -15.24 | -27.78 | -15.81 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
Journey Medical Corp | 80.00m | -4.16m | 54.65m | 58.00 | -- | 6.00 | -- | 0.6832 | -0.3095 | -0.3095 | 4.13 | 0.6498 | 0.985 | 2.27 | 4.28 | 1,379,276.00 | -5.12 | -- | -17.85 | -- | 66.22 | -- | -5.20 | -- | 0.9357 | 0.4049 | 0.5773 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
Carisma Therapeutics Inc | 15.07m | -81.22m | 55.25m | 107.00 | -- | 5.07 | -- | 3.67 | -2.01 | -2.01 | 0.3723 | 0.2623 | 0.1311 | -- | -- | 140,869.20 | -70.64 | -30.87 | -83.17 | -34.47 | -- | -- | -538.81 | -255.66 | -- | -- | 0.1717 | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
Reneo Pharmaceuticals Inc | 0.00 | -70.71m | 55.48m | 8.00 | -- | 0.6829 | -- | -- | -2.17 | -2.17 | 0.00 | 2.43 | 0.00 | -- | -- | 0.00 | -77.06 | -- | -83.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 836.12k | 2.37% |
Renaissance Technologies LLCas of 31 Mar 2024 | 209.20k | 0.59% |
Geode Capital Management LLCas of 31 Mar 2024 | 199.73k | 0.57% |
Adar1 Capital Management LLCas of 31 Mar 2024 | 198.78k | 0.56% |
Acadian Asset Management LLCas of 31 Mar 2024 | 108.69k | 0.31% |
Callan Capital LLCas of 31 Mar 2024 | 99.69k | 0.28% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 52.62k | 0.15% |
JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 50.04k | 0.14% |
Jane Street Capital LLCas of 31 Mar 2024 | 41.76k | 0.12% |
American Century Investment Management, Inc.as of 31 Mar 2024 | 40.33k | 0.11% |